Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000648212 | Skin | SCCIS | protein demethylation | 6/919 | 33/18723 | 4.88e-03 | 3.99e-02 | 6 |
GO:000821412 | Skin | SCCIS | protein dealkylation | 6/919 | 33/18723 | 4.88e-03 | 3.99e-02 | 6 |
GO:001657024 | Skin | cSCC | histone modification | 179/4864 | 463/18723 | 9.65e-10 | 3.74e-08 | 179 |
GO:004854529 | Skin | cSCC | response to steroid hormone | 135/4864 | 339/18723 | 1.34e-08 | 4.09e-07 | 135 |
GO:003052227 | Skin | cSCC | intracellular receptor signaling pathway | 108/4864 | 265/18723 | 9.21e-08 | 2.21e-06 | 108 |
GO:0030518110 | Skin | cSCC | intracellular steroid hormone receptor signaling pathway | 56/4864 | 116/18723 | 1.97e-07 | 4.28e-06 | 56 |
GO:0071383111 | Skin | cSCC | cellular response to steroid hormone stimulus | 84/4864 | 204/18723 | 1.44e-06 | 2.48e-05 | 84 |
GO:0043401110 | Skin | cSCC | steroid hormone mediated signaling pathway | 60/4864 | 136/18723 | 3.33e-06 | 5.10e-05 | 60 |
GO:000632519 | Skin | cSCC | chromatin organization | 147/4864 | 409/18723 | 4.41e-06 | 6.52e-05 | 147 |
GO:003314315 | Skin | cSCC | regulation of intracellular steroid hormone receptor signaling pathway | 37/4864 | 74/18723 | 8.06e-06 | 1.09e-04 | 37 |
GO:0030521110 | Skin | cSCC | androgen receptor signaling pathway | 24/4864 | 44/18723 | 5.16e-05 | 5.28e-04 | 24 |
GO:000633812 | Skin | cSCC | chromatin remodeling | 94/4864 | 255/18723 | 7.58e-05 | 7.26e-04 | 94 |
GO:000975518 | Skin | cSCC | hormone-mediated signaling pathway | 72/4864 | 190/18723 | 1.92e-04 | 1.61e-03 | 72 |
GO:006076514 | Skin | cSCC | regulation of androgen receptor signaling pathway | 16/4864 | 28/18723 | 4.60e-04 | 3.50e-03 | 16 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KDM4C | SNV | Missense_Mutation | rs780836880 | c.362N>A | p.Arg121His | p.R121H | Q9H3R0 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-A8-A07P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
KDM4C | SNV | Missense_Mutation | rs182255463 | c.676N>G | p.Gln226Glu | p.Q226E | Q9H3R0 | protein_coding | tolerated(0.24) | benign(0.24) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
KDM4C | SNV | Missense_Mutation | rs191848178 | c.1888N>T | p.Ala630Ser | p.A630S | Q9H3R0 | protein_coding | deleterious(0.01) | probably_damaging(0.957) | TCGA-BH-A0BG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KDM4C | SNV | Missense_Mutation | novel | c.1611N>A | p.Asn537Lys | p.N537K | Q9H3R0 | protein_coding | tolerated(0.2) | benign(0.014) | TCGA-BH-A6R8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KDM4C | SNV | Missense_Mutation | | c.1439N>A | p.Ile480Lys | p.I480K | Q9H3R0 | protein_coding | tolerated(0.95) | benign(0) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KDM4C | SNV | Missense_Mutation | | c.145N>C | p.Val49Leu | p.V49L | Q9H3R0 | protein_coding | deleterious(0) | benign(0.013) | TCGA-D8-A1X6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
KDM4C | SNV | Missense_Mutation | rs373633491 | c.1192N>A | p.Ala398Thr | p.A398T | Q9H3R0 | protein_coding | tolerated(0.34) | benign(0.001) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
KDM4C | SNV | Missense_Mutation | | c.1352C>T | p.Ser451Leu | p.S451L | Q9H3R0 | protein_coding | tolerated(0.13) | benign(0.001) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
KDM4C | insertion | Frame_Shift_Ins | novel | c.1907_1908insCTGGTGCTCTGTAAGATTTTATAAAGTGCTGTTCTTGTGGAGT | p.Thr637TrpfsTer37 | p.T637Wfs*37 | Q9H3R0 | protein_coding | | | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KDM4C | deletion | Frame_Shift_Del | | c.2601delN | p.Asn869ThrfsTer2 | p.N869Tfs*2 | Q9H3R0 | protein_coding | | | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
23081 | KDM4C | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | PYROGALLOL RED | PYROGALLOL RED | |
23081 | KDM4C | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | Pyrido[1,2-a]indole-1.-carboxylic acid analog 2 | | |
23081 | KDM4C | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | Pyrido[1,2-a]indole-1.-carboxylic acid analog 4 | | |
23081 | KDM4C | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | PYRIDINE-2,4-DICARBOXYLIC ACID | CHEMBL316034 | |
23081 | KDM4C | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | SKF-38393 | SKF-38393 | |
23081 | KDM4C | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | Pyrido[1,2-a]indole-1.-carboxylic acid analog 7 | | |
23081 | KDM4C | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | TYRPHOSTIN 23 | TYRPHOSTIN 23 | |
23081 | KDM4C | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | PMID25468267-Compound-46 | | |
23081 | KDM4C | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | N-METHOXYCARBONYLMETHYL-OXALAMIC ACID METHYL ESTER | CHEMBL92309 | 19359167 |
23081 | KDM4C | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | Pyrido[1,2-a]indole-1.-carboxylic acid analog 1 | | |